Categories: Wire Stories

LegoChem Biosciences and Amgen Enter into a Multi-Target Research Collaboration and License Agreement for the Development of Antibody-Drug Conjugates

  • LCB Grants Amgen Rights to Research, Develop, and Commercialize Antibody-Drug Conjugates Combining Targets Selected by Amgen with LCB’s Proprietary ADC Platform
  • LCB Eligible to Receive up to USD 1.25 billion

DAEJEON, South Korea–(BUSINESS WIRE)–#ADC—LegoChem Biosciences, Inc. (‘LCB’) (KOSDAQ:141080) announced on December 23 that it has entered into a research collaboration and license agreement with Amgen, whereby it granted Amgen rights to research, develop, and commercialize ADCs directed against up to 5 targets selected by Amgen based on LCB’s proprietary ConjuAll ADC technology.

Under the terms of the agreement, LCB is eligible to receive up to USD 1.25 billion including upfront, development and commercial milestone payments, and is also eligible for tiered royalties as a percentage of worldwide commercial sales by Amgen.

LCB’s clinical-stage ConjuAll ADC technology platform provides optimized site-specific conjugation, as well as cancer-selectively activating linker and payload technologies for ADCs. It overcomes the limitations associated with conventional technologies that produce heterogeneous ADCs with its greater potency, safety and stability, and enables the development ADCs with a wider therapeutic window and improved manufacturability.

“Amgen has a proven track record of bringing transformative medicines to market, and we are pleased that they selected our ADC technology to integrate with their efforts to develop next-generation ADCs,” said Yong-Zu Kim, LCB’s President and CEO. “This licensing agreement demonstrates LCB’s continued recognition as an industry-leading ADC player and further enhances our ability to innovate through global partnership as we build out our pipeline and accelerate our transformation into a fully-integrated oncology company.”

LCB has continued to build a robust ADC licensing deal flow with 12 transactions completed with a cumulative deal volume of over USD 5 billion.

Contacts

LegoChem Biosciences
Daeyoung Jeong
+82-42-861-0688
jdy@legochembio.com

Alex

Alex is a writer and digital content enthusiast who enjoys covering technology, current trends, useful tips, and topics that matter to everyday readers. With a focus on clear, informative, and easy-to-understand content, Alex aims to provide readers with practical insights and interesting perspectives across a wide range of subjects.

Recent Posts

Anthony Richardson Charged with Misdemeanor Marijuana Possession: What We Know

Key takeaways:Anthony Richardson, the Indianapolis Colts quarterback, has been charged with misdemeanor marijuana possession, according…

33 seconds ago

Avengers: Doomsday: Release News, New Team Artwork, World Series Teaser, and Pedro Pascal

Key takeaways:Marvel is marketing Avengers: Doomsday with a World Series teaser and a first poster…

11 minutes ago

Scientists Trap a Single Antimatter Particle for Months and Control Its Quantum States

Key takeaways:Physicists have trapped a single antimatter particle and kept it caged for months —…

21 minutes ago

John F. Kennedy and the Cuban Missile Crisis: The Pivotal October 22 Address and Day Eight Warning

Key takeaways:On October 22, President John F. Kennedy delivered a televised address revealing Soviet nuclear…

31 minutes ago

Gajab Raat Review and Release Guide: Manoj Bajpayee Stars in 2026 OTT Thriller

Key takeaways:Gajab Raat is a 2026 thriller film starring Manoj Bajpayee, released on OTT platforms…

41 minutes ago

Pratika Rawal Scores Unbeaten Century to Lead India Over Zimbabwe in Series Opener

Key takeaways:Pratika Rawal scored an unbeaten 100 off 96 balls to power India to victory…

52 minutes ago